Susceptibility of Candida albicans biofilms to azithromycin, tigecycline and vancomycin and the interaction between tigecycline and antifungals.
Academic Article
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Despite growing data on antimicrobial lock therapy (ALT) in treating bacterial catheter-related bloodstream infections (CR-BSIs), ALT has not been established as a treatment option for CR-BSI caused by Candida albicans. Based on our finding that high-dose doxycycline exhibited antifungal activity against mature C. albicans biofilms, we evaluated additional antibacterial agents with Gram-positive activity [azithromycin, tigecycline (TIG) and vancomycin]. After screening these antibiotics, it was found that TIG had substantial antifungal activity against mature C. albicans biofilms. Therefore, TIG was assayed alone and in combination with fluconazole (FLC), amphotericin B (AmB) or caspofungin (CAS). TIG at 2048 ?g/mL resulted in a >50% reduction in the growth of planktonic C. albicans cells. TIG inhibited the formation of biofilms from 128 ?g/mL. Against mature biofilms, 2048 ?g/mL TIG reduced metabolic activity by 84.2%. Furthermore, addition of 512 ?g/mL TIG to FLC at all concentrations tested provided additional reduction in the metabolic activity of mature biofilms. However, this was not superior to 512 ?g/mL TIG alone. TIG at 512 ?g/mL increased the antifungal effect of lower concentrations of AmB (0.03125-0.25 ?g/mL), but at 0.03125 ?g/mL and 0.0625 ?g/mL this effect was not superior to 512 ?g/mL TIG alone. TIG inhibited the antifungal effect of higher concentrations of AmB (? 2 ?g/mL). TIG at 512 ?g/mL inhibited the antifungal activity of CAS at lower concentrations (0.25-8 ?g/mL). These data indicate that high-dose TIG is highly active in vitro against planktonic cells, forming biofilms and mature biofilms of C. albicans.Published by Elsevier B.V.
